Invitation to participate in a research study: HTA use in Canada / Étude de recherche: Utilisation d’ETS au Canada

Le français suit

INVITATION

We invite you to participate in an online survey that asks your opinion about facilitators and barriers to the use of Health Technology Assessment (HTA) in Canada.

You can access the survey here: https://maastrichtuniversity.eu.qualtrics.com/jfe/form/SV_71VXNB9baxoMQ8R

The study is a collaboration between researchers from Dalhousie University, Maastricht University, Brunel University London and the Medical University of Vienna. Other studies using the same (context appropriate) questionnaire have been conducted in the Netherlands, Germany, France, U.K., Austria and Colombia. Their results are published, and their citations are provided below for your interest.

Health Technology Assessment (HTA) is an important tool that can support the allocation of scarce health care resources, yet we know that uptake is challenging. Our goal is to estimate the relative importance of facilitators and barriers that have been identified in the literature, from the perspective of Canadian stakeholders. We will do this using a best-worst scaling approach.

We estimate the time required to complete the questionnaire to be approximately 15 minutes. You will be asked four demographic questions, not including your name, and a series of best-worst scaling questions. Detailed instructions are given within the survey. The survey is completely anonymous and we ask no information that could identify you. Your participation is entirely voluntary.

The questionnaire works better on a computer screen than on a phone, if it is possible, please complete it using your computer.

We thank you in advance for your time.

Dominika Wranik (Dalhousie University) – direct questions to dwl@dal.ca

Mickael Hiligsmann (Maastricht University)

Kei Long Cheung (Brunel University)

Susanne Mayer (Medical University of Vienna)

Our previous studies

Cheung KL. Evers SMAA. De Vries H. Hiligsmann M. 2017. Most important barriers and facilitators regarding the use of Health Technology Assessment. International Journal of Health Technology Assessment in Health Care. 33(2):183-191

Dams F. Rodriquez JLG. Cheung KL. Wijnen FM. Hiligsmann M. 2018. Relevance of barriers and facilitators in the use of Health Technology Assessment in Colombia. Journal of Medical Economics. 21(5):510-517

Cheung KL. De Vries EH. Levy P. Pokhrel S. Danner J. Wentlandt L. Knufinke S. Mayer S. Hiligsmann M. 2018. Most important barriers and facilitators of HTA usage in decision-making in Europe. Expert Review of Pharmacoeconomics and Outcomes Research. doi.org/10.1080/14737167.2018.1421459

Feig C. Cheung KL. Hiligsmann M. Evers SMAA. Simon J. Mayer S. 2018. Best-worst scaling to assess the most important barriers and facilitators for the use of Health Technology Assessment in Austria. Expert Review of Pharmacoeconomics and Outcomes Research. doi.org/10.1080/14737167.2017.1375407

************************

INVITATION

Nous vous invitons à participer à un sondage en ligne afin d’avoir votre opinion sur les facilitateurs et les obstacles à l’utilisation de l’évaluation des technologies de la santé (ETS) au Canada.

Vous pouvez accéder au sondage ici : https://maastrichtuniversity.eu.qualtrics.com/jfe/form/SV_71VXNB9baxoMQ8R

L’evaluation des technologies de la santé (ETS) est un outil important qui peut appuyer l’affectation de ressources limitées en matière de soins de santé, mais nous savons que son adoption est difficile. Notre objectif est d’estimer l’importance relative des facilitateurs et des obstacles qui ont été identifiés dans la documentation, du point de vue des intervenants canadiens. Pour y arriver, nous utiliserons l’approche de mise à l’échelle allant du plus au moins important.

Nous estimons que le temps requis pour compléter le questionnaire est d’environ 15 minutes. Quatre questions démographiques vous seront adressées, sans compter votre nom, et une série de questions de mise à l’échelle du plus au moins important. Des instructions détaillées sont données dans le sondage. Le sondage est totalement anonyme et nous ne sollicitons aucune information permettant de vous identifier. Votre participation est entièrement volontaire.

L’étude est le fruit d’une collaboration entre des chercheurs de l’Université Dalhousie, de l’Université de Maastricht, de l’Université Brunel de Londres et de l’Université médicale de Vienne. D’autres études utilisant le même questionnaire (adapté au contexte) ont été menées aux Pays-Bas, en Allemagne, en France, au Royaume-Uni, en Autriche et en Colombie. Leurs résultats sont publiés et leurs citations sont fournies ci-dessous pour votre intérêt.

Nous vous remercions d’avance de votre temps.

Dominika Wranik (Dalhousie University) – adressez vos questions à dwl@dal.ca

Mickael Hiligsmann (Maastricht University)

Kei Long Cheung (Brunel University)

Susanne Mayer (Medical University of Vienna)

Nos études antérieures

Cheung KL. Evers SMAA. De Vries H. Hiligsmann M. 2017. Most important barriers and facilitators regarding the use of Health Technology Assessment. International Journal of Health Technology Assessment in Health Care. 33(2):183-191

Dams F. Rodriquez JLG. Cheung KL. Wijnen FM. Hiligsmann M. 2018. Relevance of barriers and facilitators in the use of Health Technology Assessment in Colombia. Journal of Medical Economics. 21(5):510-517

Cheung KL. De Vries EH. Levy P. Pokhrel S. Danner J. Wentlandt L. Knufinke S. Mayer S. Hiligsmann M. 2018. Most important barriers and facilitators of HTA usage in decision-making in Europe. Expert Review of Pharmacoeconomics and Outcomes Research. doi.org/10.1080/14737167.2018.1421459

Feig C. Cheung KL. Hiligsmann M. Evers SMAA. Simon J. Mayer S. 2018. Best-worst scaling to assess the most important barriers and facilitators for the use of Health Technology Assessment in Austria. Expert Review of Pharmacoeconomics and Outcomes Research. doi.org/10.1080/14737167.2017.1375407